UConn Health has started recruiting ovarian cancer patients for a phase I clinical trial of OncoImmunome, a novel genomics-driven personalized immunotherapy. Women diagnosed with stage III or IV ovarian cancer who undergo traditional surgery and chemotherapy will then receive monthly injections with personalized vaccines consisting of tumor-specific neo-epitopes identified from next-generation sequencing of patients’ tumor DNA and RNA using a bioinformatics pipeline that extends our prior work published in the Journal of Experimental Medicine.

For more details see http://today.uconn.edu/school-stories/recruitment-begins-worlds-first-ovarian-cancer-vaccine-trial/.